Freephone: 0800 257 428 Email: sales@alphatech.co.nz
Current methods for assessing the activity of SIRPalpha/CD47 checkpoint inhibitors rely on primary monocyte-derived macrophages and direct measurement of phagocytosis. These assays are laborious and highly variable due to their reliance on donor cells, complex assay protocols and unqualified assay reagents. As a result, these assays are difficult to establish in a quality-controlled setting. The SIRPalpha/CD47 Blockade Bioassay, Fc-Dependent, is a bioluminescent reporter cell-based assay used to measure the potency and stability of ligands or antibodies that bind and block SIRPalpha and CD47 interactions.
